Deputy CEO and Chief Business Officer (CBO) Anders Månsson will take up his position starting in May
RhoVac AB ("RhoVac") announces today April 25, 2019 that Anders Månsson will take up his position as CBO and Deputy CEO already in May, a month earlier than previously announced.
As previously announced, RhoVac has appointed Anders Månsson as Chief Business Officer and Deputy CEO as of June 2019. Anders is approaching the end of his current operational assignments, which has led his to be able to start his position in RhoVac already in May, i.e. one month earlier than expected. Anders has a long and solid experience from the pharmaceutical world both internationally and locally. He has worked in senior positions in major pharmaceutical companies in Sweden, Denmark, UK and Switzerland. The focus was on sales and the market, as well as on business development including distribution and license agreements, divestments and acquisition agreements over several billion SEK range. In recent years, Anders has also held a number of board positions in biotech / life science in southern Sweden. He has also held a CEO position in a stem cell company in Lund.
CEO Anders Ljungqvist comments:
- Anders Månsson's experience and expertise in business development will be of great benefit to RhoVac, and since the company is in a very exciting development phase, we are extremely pleased that Anders can start earlier than we expected!
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
E-mail: alj@rhovac.com
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published 1 August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Trade Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.